A phase II study of high-dose cisplatin and VP-16 in neuroblastoma: a report from the Société Française d'Oncologie Pédiatrique.
- 1 June 1987
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 5 (6), 941-950
- https://doi.org/10.1200/jco.1987.5.6.941
Abstract
Forty-seven children or adolescents with initial stage IV (42 patients) or stage III (five) advanced neuroblastoma (12 were progressing after relapse and 35 had never reached complete remission [CR] after conventional therapy) were included in a phase II study of the combination of high-dose VP-16 (100 mg/m2/d X 5) and high-dose cisplatin (CDDP) (40 mg/m2/d X 5). Twenty patients had received prior CDDP therapy (total dose, 100 to 640 mg/m2; median, 320 mg/m2) and 38 of 47 had bone marrow involvement when included in the study. The overall response rate was 55%, with 22% CR. Duration of response was 5 to 18 months, with a median of 10 months. Eight patients are still disease free, with a median observation time of 13 months, but all had received additional therapy after two courses of this regimen. Gastrointestinal toxicity was frequent but tolerable. Myelosuppression was severe but of brief duration, ie, nadir of neutrophils was observed at day 15 with 95% of the patients recovering a normal count before day 28, and nadir of platelet count was at day 17 with only two severe and reversible episodes of bleeding. The overall incidence of sepsis was 8% (seven of 92 courses), with no death related to infection. No acute renal failure was observed after two courses, and only three of 47 children experienced a clear reduction of renal function. After two courses, only two children showed a hearing loss in the 1,000 to 2,000 Hz range, although hearing loss above the 2,000 Hz level was frequently encountered. It is concluded that high-dose VP-16 and CDDP is an effective regimen in advanced neuroblastoma with acceptable toxicity. Phase III studies are needed in previously untreated patients. J Clin Oncol 5:941-950.This publication has 21 references indexed in Scilit:
- Early detection of cisplatin ototoxicity selected case reportsCancer, 1984
- High-Dose Cisplatin in Hypertonic SalineAnnals of Internal Medicine, 1984
- Cisplatinum‐induced renal salt wastingMedical and Pediatric Oncology, 1984
- Treatment of poor prognosis nonseminomatous testicular cancer with a “high-dose” platinum combination chemotherapy regimenCancer, 1983
- IMPROVEMENT IN THE THERAPEUTIC INDEX OF CISPLATIN (NSC-119875) BY PHARMACOLOGICALLY INDUCED CHLORURESIS IN THE RAT1983
- Sequential cyclophosphamide and doxorubicin for induction of complete remission in children with disseminated neuroblastomaCancer, 1981
- Clinical evaluation of sequentially scheduled cisplatin and vm26 in neuroblastoma: Response and toxicityCancer, 1981
- Alterations in the toxicity of cis-Dichlorodiammineplatinum-II and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administrationToxicology and Applied Pharmacology, 1981
- Clinical trial of VP 16–213 (NSC 141540) I.V. Twice weekly in advanced neoplastic disease a study by the cancer and leukemia group BCancer, 1980
- PHASE-II STUDY OF VP-16-213 IN CHILDHOOD MALIGNANT DISEASE - CHILDRENS CANCER STUDY-GROUP REPORT1979